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Cibenzoline, a new class I antiarrhythmic drug, was
administered to 24 patients with frequent (> 30th) pre-
mature ventricular complexes.Three patients discontin-
ued the medication because of epigastric distress before
repeat ambulatory electrocardiography. Of the remain-
ing 21 patients, 13 responded to 130 mg twice daily by
more than 75% suppression of premature ventricular
complex frequency and 6 additional patients responded
to 160mg twicedailyduring an open-label titration phase.
Events of ventricular tachycardia (2: 3 beats) were to-
tally suppressed in 9 of 10 patients and markedly di-
minished in the 1 remaining patient. During a double-
blind placebo-controlled crossover phase in 16 patients
(21patients minus 2 nonresponders and 3 whodeveloped
side effects), cibenzoline suppressed the number of pre-
Frequent and complex ventricular ectopic activity is asso-
ciated with increased risk of future mortality, especially
when structural cardiac disease is present (1-8). Although
definite evidence that suppression of these asymptomatic
arrhythmias decreases mortality is lacking, efforts to de-
velop better antiarrhythmic drugs are in progress (9). Ci-
benzoline, a new class I antiarrhythmic agent with a chem-
ical structure unrelated to that of other antiarrhythmic agents
([4,5 dihydro-2-(2,2-diphenyl cyclopropyl)-lH-imidazole
butanedioatel), is effective in suppressing experimentally
induced ventricular arrhythmias in the rat, cat and dog (10-
13). In open-label or single-blind studies performed on hu-
man subjects, it has been found effective in suppressing
symptomatic ventricular tachycardia unresponsive to con-
ventional drugs, preventing ventricular tachycardia induced
by programmed electrical stimulation and decreasing the
frequency of premature ventricular complexes (14-19) . We
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mature ventricular complexes per 24 hours (4,075 ±
868 to 1,758 ± 1,089, P = 0.02), the number of events
of ventricular tachycardia (31 ± 30 to 2 ± 0, p =0.01)
and the number of premature ventricular complex pairs
(61 ± 28 to 25 ± 21, p = 0.01). Cibenzoline plasma
concentration was 59 to 421 nglml in responders and
higher (387,758 and 852nglml, respectively)in the three
subjects with side effects (right bundle branch block in
one, hypotension in one, gastrointestinal upset and cen-
tral nervoussystemcomplaintsinone).Cibenzoline plasma
concentration correlated with PR interval (r = 0.55, P
= 0.0106) and corrected QT interval (r = 0.58, P =
0.0054). Further clinical investigation of this new an-
tiarrhythmic agent is needed.
performed a double-blind, placebo-controlled crossover trial
of cibenzoline in 24 patients with frequent asymptomatic
premature ventricular complexes.
Methods
Patients. With the permission of the Committee for the
Protection of Human Subjects in Research we enrolled 24
consenting patients (18 men and 6 women, mean age [ ± SD]
57 ± 11 years, range 31 to 75); 18 had coronary artery
disease, 3 had valvular disease and 3 had idiopathic pre-
mature ventricular complexes. These patients had a mini-
mum of 30 premature ventricular complexes per hour av-
eraged over two consecutive 24 hour periods. Patients with
severe angina or congestive heart failure (New York Heart
Association functional class III or IV), conduction defects,
Wolff-Parkinson-White syndrome, severe bradycardia «
50 beats/min) or recent « 3 months) myocardial infarction
were excluded. Antiarrhythmic agents were discontinued at
least five half-lives before entry into the study (> 6 days
in 15 patients and 4 days in 2 patients). Seventeen patients
had unacceptable side effects or had not responded to the
following drug regimens: quinidine, four patients; procain-
amide, four patients; both quinidine and procainamide, seven
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patients. and quinidine, procainamide and disopyramide,
two patients.
Treatment protocol. After this run-in or wash-out pe-
riod, the patients underwent a titration period and then a
double-blind placebo-controlled period (Fig. 1). During the
titration period, all patients were given 130 mg cibenzoline
twice daily for 1 week. Patients who showed at least 75%
suppression of premature ventricular complexes compared
with the initial 48 hour recording were considered re-
sponders. Patients who did not show adequate (> 75%)
premature ventricular complex suppression while taking 130
mg cibenzoline twice daily were then given 160 mg twice
daily for 1 week. Responders to either dose were entered
into the double-blind crossover phase of the study. During
this phase, patients were given either cibenzoline at the dose
found effective during the titration period or matching pla-
cebo in a double-blind randomized fashion for 1 week fol-
lowed by a second week when the patients were crossed
over from cibenzoline to placebo treatment and vice versa.
Ambulatory electrocardiography and statistical anal-
ysis. Twenty-four hour ambulatory (Holter) electrocardi-
Figure l. Study protocol and flow of patients. Be = double-
blind cihenzoline (dose as in open-label cibenzoline), 16patients;
BID = twice daily; BP = double-blind placebo (16 patients);
t B.P. = decrease in bloodpressure; EKG = electrocardiogram;
GI = gastrointestinal; HC = open-label cibenzoline, either 130
mg twice daily (13 patients) or 160 mg twice daily (8 patients);
LC = open-label cibenzoline, 130 mg twice daily; R = run-in;
RBBB ~ right bundle branch block.
3 GI side effects
ography, 12 lead electrocardiography and blood sampling
for the measurement of cibenzoline plasma concentration
were performed at the end of each week. Analysis of the
Holter tapes was performed by Cardia Data (Haddonfield,
New Jersey) in a blind fashion to quantitate the number of
premature ventricular complexes, couplets, events of Ven-
tricular tachycardia (~ 3 premature ventricular complexes
in a row) and total number of ventricular tachycardia beats
per 24 hours. This system has an acceptable sensitivity and
specificity in detecting premature ventricular complexes with
adequate accuracy and precision (20). RR, PR, QRS and
QT intervals were measured on the 12 lead electrocardio-
gram recorded at a speed of 25 mmls. Corrected QT (QTJ
interval was computed using Bazett's formula (QTc = QT/
YRR) (21). Cibenzoline plasma concentration was mea-
sured using high pressure liquid chromatography (22).
Statistical analysis. This was performed using the Sta-
tistical Analysis System program using nonparametric (pre-
mature ventricular complex-related variables) or parametric
(premature ventricular complexes/heart rate) techniques as
appropriate (23). Descriptive statistics, Spearman or Pear-
son correlation, two-way analysis of variance and Wilcoxon
test for paired data were employed (24). Analysis using log
(premature ventricular complex frequency + 1), log (pair
frequency + 1), log (ventricular tachycardia beats + 1) and
log (ventricular tachycardia events + 1) to obtain a more
normal distribution of these variables and allow the use of
parametric techniques yielded similar statistical inferences
and did not result in modification of the conclusions (Fig.
2) (25).
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Figure 2. Effect of cibenzoline on the frequency of premature
ventricularcomplexesduring the double-blind phase. 10gPVC ;=
logarithm (number of premature ventricular complexes per 24 hours
+ 1).
Results
Titration phase (Table 1). Of the 24 patients enrolled
in the study, 3 did not complete the low dose (130 mg twice
daily) phase of the titration period because of epigastric
distress (Fig. 1). Since ambulatory electrocardiography, used
to obtain efficacy data, was not performed while these three
patients were taking cibenzoline, they are not included in
further analysis. Of the remaining 21 subjects, 13 responded
with more than 75% suppression of the total number of
premature ventricular complexes per 24 hours. The re-
maining eight subjects were given 160 mg twice daily. Six
of these eight patients responded to this higher dose by more
than 75% suppression of the total number of premature
ventricular complexes. Thus, 19 of the 21 patients re-
sponded to either 130 or 160 mg cibenzoline twice daily.
Of the 19 responders, only 16 completed the double-blind
placebo-controlled phase (Fig. 1). The remaining three pa-
3
2
o
PLACEBO CIBENZOLINE
tients were unable to complete it because of side effects
(hypotension in one, right bundle branch block in one and
upper gastrointestinal complaints, tremor and "dazed feel-
ing" in one).
Ninety percent (19 of 21) of the patients responded to
either 130 or 160 mg twice daily. However, if one considers
only the patients who were able to tolerate and respond to
the medication, 66.7% (16 of 24) of the patients showed a
satisfactory response. The side effect threshold for discon-
tinuation of cibenzoline in this study was low because of
the availability of other marketed and investigational agents.
Thus, four or five patients who were instructed to discon-
tinue taking cibenzoline (excluding the patient who devel-
oped hypotension and probably the patient who developed
right bundle branch block) could probably be maintained
on this drug if other agents were not effective. Premature
ventricular complex suppression was seen in all subjects
(range 21 to 100%, median 93.4). Aggravation of premature
ventricular complexes was not seen in any patient during
the titration period. Although the total number of premature
ventricular complexes was lower in the second of the two
24 hour recordings performed at baseline (8,116 ± 1,753
versus 7,496 ± 1,526), this difference was not statistically
significant by paired Wilcoxon test. The second recording
was used for statistical comparison with the recording ob-
tained at the end of the titration phase (130 or 160 mg twice
daily).
Significant correlations of cibenzoline plasma concen-
tration with QTc (r = 0.58, P = 0.0054) and with PR
interval (r = 0.55, P = 0.°106), but not with antiarrhythmic
effect, were noted. There were no significant correlations
of the corrected QT interval (or of the change of corrected
QT interval induced by cibenzoline) with premature ven-
tricular complex suppression. There were no significant dif-
ferences in average, maximal and minimal heart rates or
QRS duration (when the patient with right bundle branch
block was excluded).
Double-blind phase (Table 1). The effects of ciben-
zoline observed during the titration period were reproduced
in the double-blind period. The average number of pre-
mature ventricular complexes per 24 hours, premature ven-
tricular complexes per 1,000 beats, number of pairs, events
of ventricular tachycardia, ventricular tachycardia beats per
24 hours and the percent of subjects with multiform beats
were lower during the placebo phase of the double-blind
period than at baseline. These differences were due, in part,
to the fact that patients who did not enter the double-blind
phase (because of lack of response or side effects) tended
to have more pronounced ventricular ectopic activity than
those who entered the double-blind phase.
Compared with placebo, (Fig. 2 and 3) cibenzoline caused
a decrease in the total number of premature ventricular com-
plexes per 24 hours, premature ventricular complexes per
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Table 1. Effect of Cibenzoline on Premature Ventricular Complexes and Electrocardiographic Time Intervals
---"
Titration Phase Double-Blind Phase
No. Run-in Cibenzoline p Value No. Placebo Cibenzoline p Value
PVC/24 h 21 7,496 ± 1,526 1,723 ± 669 0.003 16 4,075 ± 868 1,758 ± 1,089 0.02
PVC/I ,000 beats 21 66 ± 13 II ± 4 0.003 16 43 ± 9 16 ± 10 0.Q2
PVC pairs/24 h 21 133 ± 44 22 ± 13 0.008 16 61 ± 28 25 ± 21 0.02
VT events/24 h 21 65 ± 61 I ± 0 0.008 16 31 ± 30 2 ± 0 0.01
VT beats '24 h 21 371 ± 355 3 ± 0 0.001 16 241 ± 239 8 ± 0 0.01
Plasma cibenzoline (ng/ml) 21 293 ± 46 16 0 196 ± 24
PR (ms) 21 16 ± 5 177 ± II NS 16 160 ± 5 168 ± 6 NS
QTc (ms i 21 430 ± 10 435 ± II NS 16 415 ± 9 427 ± 8 NS
No. = number of; NS = not significant; PVC = premature ventricular complex; QTc = corrected QT interval; VT = ventricular tachycardia
(;;. 3 beats).
.....
-
Figure 3. Effect of cibenzoline on the number of pairs of ven-
tricular premature complexes per 24 hours during the double-blind
phase. logPAIR = logarithm (number of pairs per 24 hours +
I).
logPAIR
3
respectively; that is, 81 and 451% increase, respectively).
When all 16 patients were included, median suppression
was 89%. In these 16 subjects, premature ventricular com-
plex pairs were present in 9 subjects (56%) during placebo
administration and in 5 subjects (31%) during cibenzoline
administration. Ventricular tachycardia was present in 6
(38%) of the 16 subjects during placebo administration and
in 1 subject (0.6%) during cibenzoline treatment.
Cibenzoline trough plasma concentration was zero dur-
ing the placebo period and 186 ± 101 ng/ml (range 40 to
421) during cibenzoline administration 300 to 990 minutes
(range 729 ± 169) after the dose. The plasma concentration
was positively correlated with PR interval (r = 0.67, p =
0.0067) and corrected QT interval (r = 0.44, P = 0.0984).
The plasma concentration in the two subjects who showed
an increase in the total number of premature ventricular
complexes per 24 hours was 133 ng/ml, 300 and 645 min-
utes, respectively, after the dose. The patient with a plasma
concentrationof 40 ng/rnl (855 minutes after the dose) showed
93% suppression of premature ventricular complexes (from
5,919 to 338 premature ventricular complexes per 24 hours).
A weak positive correlation of the percent change of the
corrected QT interval to the percent premature ventricular
complex suppression was noted (r = 0.46, P = 0.0948).
Discussion
Efficacy. This double-blind placebo-controlled study
demonstrates the effectiveness of cibenzoline treatment in
suppressing premature ventricular complexes. Seventy-five
percent or more suppression was obtained in 19 (90.5%) of
21 patients during the dose titration period. This high rate
of suppression was maintained in the double-blind placebo-
controlled period in which a decrease in premature ventric-
ular complex frequency was seen in 14 (87.5%) of 16 sub-
jects. Average (median) suppression of premature ventric-
ular complexes was 93.4% in the titration period and 89%
in the double-blind period. This high degree of suppression
by cibenzoline verifies previous, mostly uncontrolled studiesCIBENZOLINEPLACEBO
o
2
1,000 heats, pairs per 24 hours, number of events of ven-
tricular tachycardia, number of ventricular tachycardia beats
per 24 hours (241 ± 239 versus 8 ± 0, p = 0.01) and of
the percent of subjects with multiform premature ventricular
beats on [13 of 16 subjects] to 50% [8 of 16 subjects]).
Compared with the blinded placebo-controlled phase, the
number of premature ventricular complexes per 24 hours
decreased in 14 subjects (29 to 100% suppression) and in-
creased in 2 subjects (9,658 to 17,517 and 194 to 1,068,
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performed with this antiarrhythmic agent (15-17) and is
higher than that reported for quinidine (26-29), the refer-
ence class I antiarrhythmic agent.
Although studies comparing cibenzoline with other an-
tiarrhythmic agents are not yet available, the degree of
suppression found here appears at least as pronounced as
that of disopyramide, procainamide and tocainide based on
previous studies (28,30,31) with these agents. In contrast
(again based on previous reports), the degree of premature
ventricular complex suppression induced by cibenzoline
administration appears less pronounced than that reported
for encainide (32) and flecainide (25,26). Despite this, and
especially in the absence of comparative studies, it appears
that cibenzoline may still obtain a place in antiarrhythmic
therapy because of its twice daily dosing and its reported
effectiveness in suppressing symptomatic ventricular tach-
yarrhythmias resistant to conventional antiarrhythmic agents
(18,19). In addition, complete suppression of ventricular
tachycardia and pairs and more than 75% decrease in pre-
mature ventricular complex frequency were observed in 12
(63.2%) of the 19 subjects in the titration period, as were
a decrease in premature ventricular complex frequency and
total elimination of ventricular tachycardia and pairs in 50%
of the patients during the double-blind placebo period; these
findings are less impressive but similar to those reported for
flecainide (68 and 70%) (25,26).
Plasma levels. The efficacy of the twice daily dosing
schedule of cibenzoline reported here is in agreement with
the long (10 to 15 hours) elimination half-life of this agent.
At steady state with twice daily dosing, using 130 mg (13
patients) or 160 mg (8 patients), average cibenzoline con-
centration (obtained approximately 11 hours, 705 ± 210
minutes after the dose) was 293.62 ± 210.11 ng/ml (range
59 to 852). With 130 mg twice daily, the level was higher
(336 ± 238 ng/ml) in the 13 patients who showed more
than 75% suppression than in the 8 who did not respond to
that dose (195 ± 94 ng/ml). In these eight nonresponders,
the level increased to 220 ± III ng/ml when they were
given cibenzoline, 160 mg twice daily. Thus, the need for
a higher dose in these patients may be due, in part, to lower
absorption, faster elimination or greater distribution of ci-
benzoline. Since oral bioavailability of cibenzoline appears
to approach 100%, these differences are more likely to be
caused, in part, by differences in renal clearance. The range
of the therapeutic trough plasma concentration was wide,
with one patient showing premature ventricular complex
suppression with a concentration as low as 59 ng/ml (720
minutes after ingestion of the twice daily dose), while the
two nonresponders in the run-in period had a concentration
of 191 and 377 ng/ml (740 and 930 minutes after the doses),
respectively. Nine responders in the titration phase and six
in the double-blind phase had a trough concentration below
190 ng/m\.
The three responders who did not complete the double-
blind period because of side effects (right bundle branch
block, hypotension, gastrointestinal and central nervous sys-
tem complaints) had high cibenzoline plasma concentrations
(387, 758, 852 ng/ml at 750, 900 and 770 minutes, re-
spectively) although they were all receiving 130 mg twice
daily. The blood urea nitrogen in one of these subjects had
increased from 31 mg/dl at run-in to 61 mg/dl when the
side effect (hypotension) occurred. Blood urea nitrogen was
normal in the other two subjects. Thus, on the basis of this
study, the therapeutic plasma concentration (approximately
11 hours after the twice daily dose) for premature ventricular
complex suppression appears to be between 150 and 700
ng/ml or between 150 and 400 ng/ml, depending on whether
one considers the right bundle branch block that occurred
in a patient with calcific aortic stenosis and a history of
aortic valve replacement and aortocoronary bypass surgery.
Similar findings (cibenzoline concentrations corresponding
to 90% premature ventricular complex suppression between
215 and 405 ng/ml in six of eight patients) were recently
reported in a dose-ranging study (33).
Side effects. Although the incidence of gastrointestinal
complications was high, serious adverse reactions due to
cibenzoline were not observed. One patient with a history
of congestive heart failure and cardiomegaly caused by se-
vere coronary artery disease developed clinically significant
hypotension requiring a short hospitalization. This isolated
case suggests that cibenzoline treatment may adversely af-
fect the hemodynamics of patients with borderline cardiac
compensation because of its negative inotropic effect ob-
served in the laboratory (10,11,17). A common side effect
was gastrointestinal upset. Although this was not severe and
did not result in vomiting in any patient, it prompted dis-
continuation of the participation of the affected patients
because of the easy availability of other agents.
The prolongation of PR and corrected QT intervals and
their positive correlation with cibenzoline plasma concen-
tration are explained by the effects of this class I antiar-
rhythmic agent on the AH interval and action potential du-
ration (10,12, 19). Although one patient developed right bundle
branch block, a significant prolongation of the QRS duration
was not noted when this patient was excluded from the
analysis. However, QRS duration was measured on tracings
recorded at a speed too slow (25 mmls) to allow detection
of small changes. A consistent association of electrocardio-
graphic changes induced by cibenzoline with antiarrhythmic
efficacy that could serve as markers for effectiveness was
not observed in this study (34). However, in the double-
blind phase, a weak positive correlation (r = 0.46, P =
0.0948) of the percent change of the corrected QT interval
to the percent premature ventricular complex suppression
was noted.
Aggravation of ventricular arrhythmias by antiar-
rhythmic drugs has been observed with most agents and
may occur in approximately 10% of patients (35). Increase
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in premature ventricular complex frequency did not occur
in any patient during the titration phase, but a 4.5-fold
increase occurred in a patient taking cibenzoline during the
double-blind phase (194 premature ventricular complexes,
zero cibenzoline plasma concentration with placebo; 1,068
premature ventricular complexes, plasma concentration 133
ng/ml with cibenzoline 160 mg twice daily).
The efficacy, twice daily dosing schedule and mild side
effects ,)f cibenzoline suggest that further clinical investi-
gation of this new antiarrhythmic drug is desirable.
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